{
  "docId": "019de076-0505-71be-a3a1-1067f47d4f96",
  "docSlug": "246b804be07776f664c6b3d8600daf3e",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 39,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 13,
  "notes": "The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0505-71be-a3a1-1067f47d4f96/15",
  "deckHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96",
  "deckJsonHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96.json",
  "deckAnchorHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "360 mg/cycle – THIO highest dose; N = 9 pts in Part A\nChemo (SOC): 70-80% incidence of Grade 3-5 side effect",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6ee596a-fa37-4832-98ef-998cc672bb72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.1,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*T-cell activation\n**Resolved within 72 hours with treatment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c507742-1b1a-4dbc-be9c-60dc3a6d29f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.1,
        "y": 0.3
      },
      "kind": "table",
      "text": "Adverse events (AE) reported – DLT window (3 weeks) | Grade\nFatigue | 1\nDecreased appetite | 1\nBlood pressure fluctuation | 1\nDyspnea | 1\nNausea | 1\nInterleukin-6 (IL-6) level increased* | 1\nRash erythematous | 1\nConstipation | 1\nMyalgia | 1\nVomiting | 2\nNausea** | 3",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79a4a905-ef77-4732-878b-050115b4b123",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "FAVORABLE SAFETY PROFILE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e1d3522-e3d6-4a8d-8734-cfe14f7b8996",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}